Dumont & Blake Investment Advisors LLC Has $789,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Dumont & Blake Investment Advisors LLC decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,275 shares of the medical research company’s stock after selling 85 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $789,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc grew its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International during the 3rd quarter worth approximately $32,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. boosted its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth $56,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 2.3 %

Shares of NYSE CRL opened at $165.38 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $159.65 and a 1 year high of $275.00. The stock has a market cap of $8.46 billion, a P/E ratio of 20.70, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38. The firm has a 50-day moving average of $184.77 and a 200 day moving average of $196.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.72 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CRL shares. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective on the stock. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $204.38.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).